SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-054632
Filing Date
2023-11-27
Accepted
2023-11-27 08:45:17
Documents
16
Period of Report
2023-11-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20015189_8k.htm   iXBRL 8-K 37738
2 EXHIBIT 10.1 ef20015189_ex10-1.htm EX-10.1 73869
3 EXHIBIT 99.1 ef20015189_ex99-1.htm EX-99.1 18370
7 image0.jpg GRAPHIC 15950
8 image00002.jpg GRAPHIC 6484
  Complete submission text file 0001140361-23-054632.txt   324979

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ocup-20231120.xsd EX-101.SCH 3865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20231120_lab.xml EX-101.LAB 22546
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20231120_pre.xml EX-101.PRE 16044
10 EXTRACTED XBRL INSTANCE DOCUMENT ef20015189_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 231437408
SIC: 2834 Pharmaceutical Preparations